Get started
Author

William J. Canestaro

Observed names: W Canestaro, W. Canestaro, W. J. Canestaro, W.J. Canestaro, WJ Canestaro, Will Canestaro, William Canestaro, William J Canestaro
Observed institutions: Brigham and Women's Hospital, Harvard University, University of Washington, Yale University, Washington Research Foundation, CVS Health (United States), Yale New Haven Health System, Ziopharm Oncology (United States)
ORCID: 0000-0002-6577-1047
Observed ORCID: 0000-0002-6577-1047
OpenAlex ID: A5076531860
Drug Treatment of Idiopathic Pulmonary Fibrosis
2016 · William J. Canestaro, Sara H. Forrester, et al. · CHEST Journal · 186
Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
2013 · William J. Canestaro, Amanda R. Patrick, et al. · Circulation Cardiovascular Quality and Outcomes · 84
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review
2014 · William J. Canestaro, Melissa A. Austin, et al. · Genetics in Medicine · 80
Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels
2014 · Bo Wang, William J. Canestaro, et al. · JAMA Internal Medicine · 51
Systematic review: patient‐reported outcome measures in coeliac disease for regulatory submissions
2016 · W. J. Canestaro, T. C. Edwards, et al. · Alimentary Pharmacology & Therapeutics · 36
PDF
R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life
2021 · Ciaran Scallan, Lauren Strand, et al. · European Respiratory Journal · 28
PDF
Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis
2017 · William J. Canestaro, Nathaniel Hendrix, et al. · Journal of Clinical Epidemiology · 27
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib
2017 · J. J. Carlson, W. Canestaro, et al. · Journal of Medical Economics · 26
PDF
Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment
2024 · William J. Canestaro, Randall J. Bateman, et al. · Population Health Management · 23
Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing
2012 · William J. Canestaro, David G. Brooks, et al. · Journal of Personalized Medicine · 17
PDF
Implications of employer coverage of contraception: Cost‐effectiveness analysis of contraception coverage under an employer mandate
2016 · W. Canestaro, E. Vodicka, et al. · Contraception · 15
Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention
2013 · Nihar R. Desai, William J. Canestaro, et al. · Circulation Cardiovascular Quality and Outcomes · 15
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)
2015 · William J. Canestaro, Daryl E. Pritchard, et al. · Journal of Managed Care & Specialty Pharmacy · 11
PDF
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
2016 · Josh John Carlson, William Bruce Wong, et al. · Journal of Clinical Oncology · 6
Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use.
2017 · Lauren Chin, Beth Devine, et al. · PubMed Central · 3
Healthcare Payers: A Gate or Translational Bridge to Personalized Medicine?
2011 · William J Canestaro, Lori A Martell, et al. · Personalized Medicine · 3
Adjustment of publication bias using a cumulative meta-analytic framework
2022 · W. J. Canestaro, E. B. Devine, et al. · International Journal of Technology Assessment in Health Care · 2
Drug Therapy for Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review And Network Meta-Analysis
2015 · W.J. Canestaro, S. Forrester, et al. · Value in Health · 2
Inflation reduction act impact on pharmaceutical investment: insights from investor interviews
2025 · William J Canestaro, Julie A Patterson, et al. · Health Affairs Scholar · 1
PDF
EE284 Exploring the Value of a Novel Health Technology Tool to Support Diagnosis of Autism Spectrum Disorder
2023 · Z. Elsisi, W. Canestaro, et al. · Value in Health · 1
PDF
Capsule Commentary on Phibbs et. al., At-Home versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS)
2016 · William J. Canestaro · Journal of General Internal Medicine · 1
PDF
Hpr133 the Potential Early Impact of the Inflation Reduction Act on Buy-side Valuation Methodologies and Transaction Structuring in the Pharmaceutical Industry
2026 · William J. Canestaro, Julie Patterson, et al. · Value in Health
HPR65 Early Signals of Inflation Reduction Act Impact on Pharmaceutical Investment and Prioritization Decisions
2025 · William J. Canestaro, Jon D. Campbell, et al. · Value in Health
Applying early health technology assessment (e-HTA) to inform investment in novel health technologies in the US
2025 · Zizi Elsisi, William Canestaro, et al. · International Journal of Technology Assessment in Health Care
PDF
EE144 Chimerism Testing for Patients With Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Cost-Utility Analysis
2024 · J Fulcher, S Kanaan, et al. · Value in Health
PDF
Works count: 38
Citation count: 618
H-index: 12
I10-index: 13
Year
Topic
Type